<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Two MoAbs directed towards human B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> have been studied in a preclinical animal model to evaluate their potential for in vivo imaging and therapy of B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Anti-B1 reacts with virtually <z:hpo ids='HP_0000001'>all</z:hpo> immunoglobulin-bearing <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and non-T <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Anti-J5 reacts with the common <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> antigen found on non-T <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> and follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Anti-T1 which recognizes the CD5 antigen on most T-cell <z:hpo ids='HP_0001909'>leukemias</z:hpo> and <z:hpo ids='HP_0002665'>lymphomas</z:hpo> was used as a control antibody </plain></SENT>
<SENT sid="4" pm="."><plain>These monoclonal antibodies were radiolabeled with 125I or 131I by the ICl method </plain></SENT>
<SENT sid="5" pm="."><plain>Namalwa (B-cell) and MOLT-4 (T-cell) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were grown s.c. in irradiated <z:mp ids='MP_0003815'>nude</z:mp> mice </plain></SENT>
<SENT sid="6" pm="."><plain>The highest tissue concentration of 125I-labeled anti-J5 in Namalwa-bearing mice was in blood and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>/blood ratio ranged from 0.7-1.2, with the highest ratio 4 days after injection </plain></SENT>
<SENT sid="8" pm="."><plain>Pharmacokinetic analysis indicated that the t1/2 beta of anti-J5 from blood and other tissues ranged from 40-50 h, while the t1/2 beta for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> averaged 65 h </plain></SENT>
<SENT sid="9" pm="."><plain>The area under the curve of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> was 2- to 5-fold higher than the area under the curve of liver, kidney, skin, and muscle </plain></SENT>
<SENT sid="10" pm="."><plain>The peak tissue levels of 125I-labeled anti-B1 in Namalwa-bearing mice were again in blood and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and 6 days following injection more than 5-fold greater activity was found in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> compared to <z:mpath ids='MPATH_458'>normal</z:mpath> tissues other than blood </plain></SENT>
<SENT sid="11" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>/blood ratio was 1.2 and 0.7 at 4 and 6 days after injection </plain></SENT>
<SENT sid="12" pm="."><plain>125I-labeled anti-B1 showed minimal uptake in antigen-negative MOLT-4 tumors and 125I-labeled anti-T1 showed little uptake in Namalwa <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Scintigraphic images were obtained following the injection of 131I-labeled anti-J5 and anti-B1 in <z:mp ids='MP_0003815'>nude</z:mp> mice bearing Namalwa <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>These results indicate that radiolabeled anti-J5 and anti-B1 show promise as diagnostic and possibly therapeutic agents for human B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, although there may be a limitation to clinical utility due to cross-reactivity with some <z:mpath ids='MPATH_458'>normal</z:mpath> cells </plain></SENT>
</text></document>